Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Metastatic Colorectal Cancer.

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Metastatic Colorectal Cancer.
Read the original article

Tags:

Previous Article

(Curcumin + doxorubicin) by Immix BioPharma for Triple-Negative Breast Cancer (T...

Next Article

(Curcumin + doxorubicin) by Immix BioPharma for Colorectal Cancer: Likelihood of...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The U.S. must raise federal alcohol taxes to address the alarming rise in alcohol use

Opinion: The U.S. must raise federal alcohol taxes to a...

Dec 21, 2023

STAT+: Illumina to lay off 10% of research and development team in bid to cut costs by $100 million

STAT+: Illumina to lay off 10% of research and developm...

Jun 26, 2023

J&J and Legend’s Carvykti scores early line approval for MM by FDA

J&J and Legend’s Carvykti scores early line approval fo...

Apr 9, 2024